Stock data
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX) reported net income of -US$33.85M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$35.27M | -US$33.85M | — |
| 2024 | — | — | -US$60.12M | -US$55.85M | — |
| 2023 | — | — | -US$42.79M | -US$37.54M | — |
| 2022 | — | — | -US$62.68M | -US$62.02M | — |
| 2021 | — | — | -US$56.22M | -US$57.78M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$5.45M | — |
| 2026-03-31 | — | -US$3.45M | — |
| 2025-12-31 | — | -US$6.46M | — |
| 2025-09-30 | — | -US$7.69M | — |
| 2025-06-30 | — | -US$9.77M | — |
| 2025-03-31 | — | -US$9.93M | — |
| 2024-12-31 | — | -US$15.81M | — |
| 2024-09-30 | — | -US$15.11M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.